Lars Fruergaard Jørgensen, CEO of Novo Nordisk, explains the critical issue of obesity as a complex disease influenced by numerous factors. He discusses innovative drug developments that aid in both diabetes and obesity management, emphasizing their benefits and the challenges of access in Europe. Jørgensen also shares insights on navigating cultural dynamics in leadership and the importance of supporting non-linear career paths for young professionals. His vision blends corporate responsibility with a commitment to equitable healthcare access.

CEOs of Novo Nordisk and AstraZeneca discuss the Sustainable Markets Initiative Health Systems Task Force, decarbonizing the supply chain, and innovation in the pharmaceutical industry towards achieving a net-zero world.